What Is Dynorphin A? Definition and What Research Reports
Dynorphin A is an endogenous opioid peptide produced in the nervous system from the precursor protein prodynorphin. Its best-known form is the 17-amino-acid Dynorphin A (1-17), which binds the kappa opioid receptor. Published laboratory work describes both opioid receptor signalling and separate, non-opioid actions on membranes, bradykinin receptors and cellular pathways. It is studied in pain, opioid withdrawal, neurodegeneration and neuroendocrine models. This glossary entry is definitional only and does not describe use in people.
Definition
Dynorphin A is a naturally occurring (endogenous) opioid peptide found in the central and peripheral nervous systems of mammals. It is cleaved from a larger precursor protein called prodynorphin, and the form most often studied is Dynorphin A (1-17) — a chain of 17 amino acids beginning with the Tyr-Gly-Gly-Phe sequence shared by other opioid peptides. Dynorphin A is generally described as the principal endogenous ligand for the kappa (κ) opioid receptor, although a substantial body of laboratory work has also characterised actions that do not depend on opioid receptors at all. In peptide research, "Dynorphin A" is used both as the name of the native peptide and as the parent scaffold for shortened or chemically modified analogues used as pharmacological tools.
What Class of Molecule It Is and Where It Comes From
Dynorphin A belongs to the endogenous opioid peptide family, alongside the enkephalins and beta-endorphin. Each family derives from a distinct precursor gene product; dynorphins come from prodynorphin. Enzymatic processing of prodynorphin yields several related peptides, including Dynorphin A (1-17) and shorter fragments such as Dynorphin A (1-13) and Dynorphin A (1-8), which differ in receptor behaviour.
Its distribution is not limited to neurons. Immunohistochemical work has mapped dynorphin-A-immunoreactive nerve terminals onto the neuronal somata of the rat mesencephalic trigeminal nucleus, indicating anatomical positioning within primary sensory circuitry (PMID 18455871). Beyond the nervous system, researchers have reported release of Dynorphin A, alongside methionine-enkephalin, from immune cells in a rat model of inflammatory pain, framing opioid peptides as signals that can originate in inflamed peripheral tissue rather than only in the brain and spinal cord (PMID 11514079).
How the Term Is Used in Peptide Research
Three usages are common in the literature:
- The native peptide. Dynorphin A (1-17) as an endogenous signalling molecule measured in tissue or released under experimental conditions.
- A pharmacological probe. Synthetic Dynorphin A applied to cells, slices or animals to interrogate kappa opioid receptor signalling and downstream effects.
- A medicinal-chemistry scaffold. Truncated, cyclised or substituted analogues built from the Dynorphin A sequence to separate opioid from non-opioid activity.
Common Forms Named in the Literature
| Term | What it refers to |
|---|---|
| Dynorphin A (1-17) | Full-length 17-residue peptide; the form most frequently studied in pain models |
| Prodynorphin | Precursor protein from which dynorphin peptides are enzymatically released |
| [des-Arg⁷]Dynorphin A analogues | Sequence-modified series examined for kappa opioid receptor structure–activity relationships |
| Cyclic non-opioid analogues | Constrained peptides designed to address bradykinin receptors rather than opioid receptors |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
Pain and Nociception
Dynorphin A appears in pain research on both sides of the ledger. A 2023 report in Molecular Pain examined the pain-related behavioural and electrophysiological actions of Dynorphin A (1-17), describing effects on nociceptive signalling that the authors attributed to more than kappa opioid receptor activation alone (PMID 37351900). Earlier mouse work reported that nociceptin and Dynorphin A (1-17) each produced antianalgesia — a reduction in the analgesic response — and that researchers concluded the two peptides acted through independent systems (PMID 11860156). A separate rat study measured Dynorphin A levels in brain tissue alongside nociceptive testing after paracetamol administration, linking a common analgesic to changes in endogenous dynorphin content (PMID 11384206).
Non-Opioid Actions
A recurring theme is that Dynorphin A does things that opioid antagonists do not block. Work published in 2022 reported that Dynorphin A induced membrane permeabilization through the formation of proteolipidic pores, combining electrophysiological recordings with computational simulations to describe how the peptide interacts directly with lipid bilayers (PMID 35024095). Medicinal chemists have exploited this separation: a 2016 study described cyclic non-opioid Dynorphin A analogues designed as ligands for the bradykinin receptors, a receptor family unrelated to opioid signalling (PMID 27756562).
Structure–Activity Work at the Kappa Receptor
On the opioid side, a 2016 Journal of Medicinal Chemistry paper reported structure–activity relationships for a series of [des-Arg⁷]Dynorphin A analogues at the kappa opioid receptor, mapping how specific sequence changes altered receptor interaction (PMID 27797517). This kind of systematic substitution work is how the field distinguishes which residues carry opioid activity and which carry the peptide's other properties.
Mutant Peptides and Neurodegeneration
Mutations in the prodynorphin gene have been associated with spinocerebellar ataxia. A 2021 study in Biomedicines functionally characterised spinocerebellar-ataxia-associated Dynorphin A mutant peptides, comparing mutant forms against the wild-type peptide in cell-based assays (PMID 34944698).
Opioid Withdrawal and Microglia
Dynorphin A also features in addiction neurobiology. A 2021 study reported that bulleyaconitine A inhibited morphine-induced withdrawal symptoms, conditioned place preference and locomotor sensitization in rodents, and the researchers linked these effects to microglial Dynorphin A expression (PMID 33716748).
Neuroendocrine and Cellular Studies
In female rats, paraventricular Dynorphin A neurons were reported to mediate suppression of luteinising hormone (LH) pulses induced by hindbrain glucoprivation, placing the peptide within circuits that link metabolic status to reproductive hormone output (PMID 32894768). In a quite different setting, a 2025 cell study reported that Dynorphin A impaired mitochondrial biogenesis in osteosarcoma cells by increasing SP-1 (PMID 40836639).
Adverse Effects and Safety Signals: What Studies Report
The verified literature summarised here consists of animal, cell-culture and computational work rather than human safety trials, so it does not describe an adverse-event profile in people. What it does report are mechanistic findings that researchers themselves flag as potentially damaging in a laboratory context: direct membrane permeabilization through proteolipidic pore formation (PMID 35024095), impaired mitochondrial biogenesis in an osteosarcoma cell line (PMID 40836639), and antianalgesic rather than analgesic behavioural effects in mice (PMID 11860156). None of these observations has been translated into a characterised human tolerability profile in the sources cited on this page.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appScope and Limitations
Dynorphin A is a research subject, not an approved medicine. The studies cited here were conducted in rodents, isolated cells, tissue preparations or in silico models; findings in those systems do not automatically transfer to humans. Because the peptide has both opioid-receptor-dependent and opioid-receptor-independent actions, results from one experimental design frequently do not generalise to another — which is why the literature contains apparently opposing descriptions of its effect on pain. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or medical decision.
References
- Pain-related behavioral and electrophysiological actions of dynorphin A (1-17) (Molecular Pain, 2023)
- Functional Characterization of Spinocerebellar Ataxia Associated Dynorphin A Mutant Peptides (Biomedicines, 2021)
- Cyclic non-opioid dynorphin A analogues for the bradykinin receptors (Bioorganic & Medicinal Chemistry Letters, 2016)
- The effect of paracetamol on nociception and dynorphin A levels in the rat brain (Neuropeptides, 2001)
- Methionine-enkephalin- and Dynorphin A-release from immune cells and control of inflammatory pain (Pain, 2001)
- Dynorphin A Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP-1 (Journal of Biochemical and Molecular Toxicology, 2025)
- Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression (Frontiers in Pharmacology, 2021)
- Dynorphin-A immunoreactive terminals on the neuronal somata of rat mesencephalic trigeminal nucleus (Neuroscience Letters, 2008)
- Nociceptin and dynorphin A(1-17) produce antianalgesia through independent systems in mice (Life Sciences, 2002)
- Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor (Journal of Medicinal Chemistry, 2016)
- Dynorphin A induces membrane permeabilization by formation of proteolipidic pores (Computational and Structural Biotechnology Journal, 2022)
- Paraventricular Dynorphin A Neurons Mediate LH Pulse Suppression Induced by Hindbrain Glucoprivation in Female Rats (Endocrinology, 2020)
Frequently asked questions
Is Dynorphin A a natural peptide or a synthetic one?▾
Both descriptions apply depending on context. Dynorphin A is an endogenous opioid peptide produced in mammalian tissue from the precursor protein prodynorphin, and researchers have reported its release from immune cells in a rat inflammatory pain model (PMID 11514079). Synthetic versions and modified analogues are also made for laboratory use, such as the [des-Arg7] series studied at the kappa opioid receptor (PMID 27797517).
Which receptor does Dynorphin A act on?▾
Dynorphin A is generally described as the main endogenous ligand at the kappa opioid receptor, and structure–activity studies have mapped how sequence changes in analogues alter that interaction (PMID 27797517). However, researchers have also built cyclic Dynorphin A analogues that are explicitly non-opioid and instead target bradykinin receptors, showing the scaffold is not limited to opioid signalling (PMID 27756562).
Does Dynorphin A reduce pain in animal studies?▾
The reported picture is mixed. A 2023 study examined pain-related behavioural and electrophysiological actions of Dynorphin A (1-17) and described effects extending beyond kappa receptor activation (PMID 37351900). Separately, a mouse study reported that Dynorphin A (1-17) produced antianalgesia — a reduction in analgesic response — through a system independent of nociceptin (PMID 11860156).
What are Dynorphin A's non-opioid actions?▾
Researchers have reported that Dynorphin A can permeabilize membranes by forming proteolipidic pores, characterised using electrophysiology and computational simulation (PMID 35024095). A 2025 cell study also reported that Dynorphin A impaired mitochondrial biogenesis in osteosarcoma cells by increasing SP-1 (PMID 40836639). Neither mechanism requires opioid receptor binding.
Why is Dynorphin A studied in spinocerebellar ataxia?▾
Mutations affecting the prodynorphin gene have been linked to spinocerebellar ataxia. A 2021 study functionally characterised spinocerebellar-ataxia-associated Dynorphin A mutant peptides, comparing mutant forms with the wild-type peptide in laboratory assays to understand how the sequence changes alter peptide behaviour (PMID 34944698).
Has Dynorphin A been studied outside pain research?▾
Yes. In female rats, paraventricular Dynorphin A neurons were reported to mediate suppression of luteinising hormone pulses after hindbrain glucoprivation, connecting the peptide to metabolic–reproductive signalling (PMID 32894768). A separate rodent study linked microglial Dynorphin A expression to reduced morphine withdrawal signs and conditioned place preference following bulleyaconitine A (PMID 33716748).
Is Dynorphin A an approved medicine?▾
No. The literature summarised here is preclinical — rodent, cell-culture, tissue and computational work, such as immunohistochemical mapping of dynorphin-A terminals in the rat trigeminal nucleus (PMID 18455871) and measurement of brain dynorphin A levels in rats (PMID 11384206). This page is educational only and is not medical advice; medical questions belong with a licensed physician.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.